Olanzapine for Chemotherapy-Induced Nausea and Vomiting by Bossaer, John B.
East Tennessee State University
Digital Commons @ East Tennessee State University
ETSU Faculty Works Faculty Works
10-5-2016
Olanzapine for Chemotherapy-Induced Nausea
and Vomiting
John B. Bossaer
East Tennessee State University, bossaer@etsu.edu
Follow this and additional works at: https://dc.etsu.edu/etsu-works
Part of the Oncology Commons, and the Pharmacy and Pharmaceutical Sciences Commons
This Article is brought to you for free and open access by the Faculty Works at Digital Commons @ East Tennessee State University. It has been
accepted for inclusion in ETSU Faculty Works by an authorized administrator of Digital Commons @ East Tennessee State University. For more
information, please contact digilib@etsu.edu.
Citation Information
Bossaer, John B.. 2016. Olanzapine for Chemotherapy-Induced Nausea and Vomiting. New England Journal of Medicine. Vol.375(14).
1395-1396. https://doi.org/10.1056/NEJMc1610341 ISSN: 0028-4793
Olanzapine for Chemotherapy-Induced Nausea and Vomiting
Copyright Statement
From New England Journal of Medicine, John B. Bossaer, Olanzapine for Chemotherapy-Induced Nausea and
Vomiting, Volume 375 No. 14, Page No. 1395-1396 Copyright © 2016 Massachusetts Medical Society.
Reprinted with permission.
This article is available at Digital Commons @ East Tennessee State University: https://dc.etsu.edu/etsu-works/2312
Correspondence
n engl j med 375;14 nejm.org October 6, 2016 1395
Somewhat reduced sensitivity to ticagrelor that 
is associated with greater platelet reactivity (i.e., a 
higher occurrence of high residual platelet reac-
tivity during treatment) has been reported in pa-
tients older than 70 years of age, independent of 
sex, body-mass index, diabetes, cholesterol and fi-
brinogen levels, smoking, renal function, previous 
myocardial infarction, concomitant cardiovascu-
lar therapy, hemoglobin levels, and platelet count.1 
Similarly, an age older than 70 years has been 
inversely associated with the probability of low 
platelet reactivity.2 Given the above-mentioned 
results of the SOCRATES trial, data stratification 
according to a 70-year age limit may reveal a 
clearer distinction. Regardless of either a 65-year 
or 70-year limit, the possible superiority of ti-
cagrelor over aspirin in reducing cardiovascular 
risk among younger patients should be explored 
further.
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The authors reply: As noted by Landman and 
Kleefstra, ticagrelor appeared more effective than 
aspirin in the subgroup of patients who had tak-
en aspirin previously. Although this may relate to 
a greater effect of ticagrelor in patients who did 
not have a response to aspirin, it could also rep-
resent a benefit from ticagrelor on a background 
of residual antiplatelet effects from aspirin, which 
persist for more than a week after a dose. A more 
detailed analysis is planned.
PPIs were used at baseline by 585 of 6549 pa-
tients (8.9%) in the ticagrelor group and by 613 of 
6581 patients (9.3%) in the aspirin group. There 
were no significant differences in major hemor-
rhage or in major and minor hemorrhage com-
bined according to treatment in either PPI sub-
group. Thus, the data do not support the use of 
aspirin by those taking a PPI, though the statis-
tical power is limited.
As noted by Čulić, we originally evaluated the 
effect of treatment among three age strata on the 
basis of an analysis plan that was established a 
priori, and ticagrelor was nominally superior to 
aspirin in patients younger than 65 years of age, 
with a trend toward significance in patients 65 to 
75 years of age. When the population is stratified 
at 70 years of age, among those 70 years of age 
or younger the primary outcome event occurred 
in 6.2% of those assigned to ticagrelor and 7.1% of 
those assigned to aspirin (P = 0.09). Among those 
older than 70 years of age, event rates were 7.8% 
with ticagrelor and 8.2% with aspirin (P = 0.45). 
The interaction between age group and treatment 
was not significant (P = 0.63). Thus, we cannot 
confirm that age has an effect when dichotomized 
at 70 years.
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Olanzapine for Chemotherapy-Induced Nausea and Vomiting
To the Editor: Navari and colleagues (July 14 
issue)1 report on the use of olanzapine for the pre-
vention of chemotherapy-induced nausea and vom-
iting. The methods allowed for real-world use of 
neurokinin-1 (NK1)–receptor antagonists, either 
oral aprepitant or intravenous fosaprepitant. Al-
though the dosing of dexamethasone is consis-
tent on days 1 and 2 between agents, it should 
differ between an oral dose of 8 mg daily on days 
3 and 4 in patients receiving aprepitant and an 
oral dose of 8 mg twice daily on days 3 and 4 in 
those receiving fosaprepitant.2 Because fosapre-
pitant is given only on day 1, the drug interaction 
with dexamethasone is absent on days 3 and 4, 
thus necessitating a higher dexamethasone dose. 
Per the study protocol (available with the full text 
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of the article at NEJM.org), the dexamethasone dos-
ing was the same regardless of which NK1-receptor 
antagonist was used. This approach would not 
have affected the results for the evaluation period 
of 0 to 24 hours but in effect resulted in a substan-
dard comparator group for the evaluation of de-
layed nausea and vomiting (in the period of 0 to 
120 hours). Anecdotally, this discrepancy in dexa-
methasone dosing occurs commonly in commu-
nity practices, and it is important for clinicians to 
remain diligent with regard to the dosing of sup-
portive care medications in patients receiving che-
motherapy.
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The authors reply: Bossaer raises the issue of 
using a higher dose of dexamethasone on days 3 
and 4 after chemotherapy than on days 1 and 2 
when intravenous fosaprepitant is used in lieu of 
3 days of oral aprepitant. In a trial by Grunberg 
et al.1 in which intravenous fosaprepitant was com-
pared with 3 days of oral aprepitant and shown to 
be noninferior for the control of chemotherapy-
induced nausea and vomiting in the delayed eval-
uation period and the overall period, dexameth-
asone was given in higher doses on days 3 and 
4 than on days 1 and 2 in the fosaprepitant group. 
However, a subgroup analysis in our trial of olan-
zapine showed no difference in results among pa-
tients who received fosaprepitant and those who 
received aprepitant. In addition, recent studies 
have suggested that multiple days of dexametha-
sone may not be necessary for the prevention of 
chemotherapy-induced nausea and vomiting.2,3
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State Regulations and Opioid Use among Disabled Adults
To the Editor: Meara et al. (July 7 issue)1 con-
clude that state laws such as those supporting 
prescription-drug monitoring programs (PDMPs) 
do not reduce hazardous opioid use or nonfatal 
overdose. These conclusions may cause clinicians 
and policymakers to discount the value of PDMPs. 
In addition, the findings of the study diverge from 
those of other recent studies assessing the effect 
of PDMPs.2-4 Patrick et al., using a more rigorous 
design to account for the specific features of 
PDMPs, found that these programs were associ-
ated with declines in deaths from opioid over-
dose.3 Bao et al., using a nationally representative 
sample — not only Medicare beneficiaries with 
disabilities — found a 30% decline in the prescrib-
ing of Schedule II opioids after the implementation 
of PDMPs.4 The decision by Meara et al. to include 
multiple laws regarding controlled substances in a 
single analysis presupposes that each law within 
a category is identical. Categorizing laws as en-
acted or not enacted ignores heterogeneity across 
laws of the same type. It is the components of a 
law and the implementation and enforcement of 
those components that matter. The null findings 
of the study may be a by-product of these meth-
odologic choices. Additional investigation is need-
ed to further evaluate the effects of PDMPs and 
other state-level interventions.
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